StockData
Kyverna Therapeutics, Inc. logo

Kyverna Therapeutics, Inc. (KYTX) stock

KYTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 2/30
$4.70−0.06 (-1.26%)

Close on Nov 17, 2026Market cap $290.66MP/E –Yield –

Kyverna Therapeutics profit margin

Profit margin (net margin) is net income as a percentage of revenue.

No profit margin figures for Kyverna Therapeutics

Kyverna Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Kyverna Therapeutics figures

See a number that looks wrong?